Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma
Everson R, Antonios J, Lisiero D, Soto H, Scharnweber R, Garrett M, Yong W, Li N, Li G, Kruse C, Liau L, Prins R. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro-Oncology 2015, 18: 368-378. PMID: 26330563, PMCID: PMC4767237, DOI: 10.1093/neuonc/nov153.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, NeoplasmAzacitidineCell Line, TumorDecitabineDisease Models, AnimalGlioblastomaHumansImmunotherapy, AdoptiveMiceT-LymphocytesConceptsNY-ESO-1NY-ESO-1-specific T cellsCells treated with decitabineDiffusely infiltrating tumor cellsAdoptive T cell therapyIntracranial human glioma xenograftsT-cell therapyDemethylating agent decitabineTumor rejection antigensGlioma-bearing miceSignificant survival benefitSquamous cell carcinomaPhenotype of lymphocytesT cell traffickingInfiltrating tumor cellsIdeal treatment modalityReal-time cytotoxicity assayHuman glioma xenograftsHuman glioblastoma cell culturesLong-term survivalClinically feasible strategyLong-term survival of animalsIn vitro treatmentTreatment of glioblastomaGlioblastoma cell cultures